Nuformix plc
NFX:LN

Dr Christopher Blackwell

Executive Chairman

Chris Blackwell became Executive Chairman in June 2020 having previously been interim Chairman since February 2020 and a Non-Executive Director of Nuformix plc since May 2018. Chris was formerly CEO of Vectura Group Plc from February 2004 to June 2015. Having completed his PhD studies at the University of Bath, sponsored by ICI Pharmaceuticals (now Astra Zeneca), Chris began his pharmaceutical career with GSK as a Clinical Pharmacologist, moving to Hoffman La-Roche as UK Director of Global Project Management and then Scotia Pharmaceuticals, before joining Vectura. As CEO over the space of 11 years, Chris built a team that refocused Vectura’s research-led model into a billion-dollar market capitalised commercially-driven company.

Dr Karl Keegan

Non-Executive Director

Karl has over 25 years of experience working in senior roles in the life sciences industry. Karl spent 12 years as a highly regarded sell-side life sciences research analyst, researching and helping finance companies across the UK, Europe, USA and Canada. Since then, primarily in CFO roles, he has focused on corporate development, and has a successful track record of devising and implementing M&A and finance projects, delivering value across all aspects of business strategy, highlights include the sale of Minster pharmaceuticals plc to Proximagen plc, multiple financings to support a new strategy for Pharming Group NV and leadership of M&A deals at Vectura Group plc. Karl is the Senior Independent Director. External appointments: Karl is CEO of HOX Therapeutics Ltd and a Non-Executive Director of Novai Ltd

Dr Anne Brindley

Chief Executive Officer

Anne has over 30 years’ experience in Big Pharma, Biotech and smaller R&D companies, with a proven international track record of leading organisations through strategic change and driving projects and portfolios through discovery and development to market. Anne was previously CEO of Advent Pharmaceuticals Pty Ltd, Melbourne, Australia, a specialty R&D company focused on generic inhaled products for global markets. In that role, Anne led a successful sale of the products and assets to AuroScience Pty Ltd, Melbourne, Australia, a wholly owned subsidiary of Aurobindo Pharma USA Inc. She subsequently became CEO of AuroScience Pty Ltd. Before moving to Advent, Anne was a Board member and Managing Director of Respivert Ltd, a subsidiary of Janssen Pharmaceuticals (part of Johnson & Johnson, Inc), where she was responsible for leadership and operations of the company, including discovery / development programmes spanning three novel classes of drug for idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and asthma, as well as out-licensing activities. Prior to this, Anne occupied the role of Vice President and Head of Inhalation Products. Anne’s earlier career included roles as Executive Vice President, Pharmaceutical Development & Project Management at Skyepharma plc, a specialty pharma company developing innovative oral and inhalation products, and senior positions in Product Development at AstraZeneca PLC. Prior to this, Anne worked at GlaxoSmithKline plc.

Dr Julian Gilbert, Non-Executive Director

Non-Executive Director

Dr Julian Gilbert, Non-Executive Director, has more than 30 years of commercial and technical experience in the pharmaceutical industry gained at a number of companies including Chiroscience Plc, Mundipharma International Limited, British Technology Group plc (BTG) and Smith Kline & French (now GlaxoSmithKline plc). Most recently, Julian was co-founder and CEO of Acacia Pharma Group plc (Acacia), raising c.£100m in private and public funding and leading its flotation on Euronext in 2018. Prior to Acacia, he was co-founder and Commercial Director of Arakis Limited which was sold to Sosei in 2005 for £107 million. Julian has worked in business development since 1992 and has led multiple business development projects. Julian has a degree in pharmacy and a PhD in pharmaceutics, both from the University of Nottingham. Committees: Julian is as a member of the Nomination & Audit Committees.

Dr Joanne Holland

Chief Scientific Officer

Jo received a PhD in Chemistry from the University of Leeds sponsored by Pfizer. She joined the process R&D group at Millennium Pharmaceuticals before moving to a combined research and commercial role at Stylacats Limited. Following this Jo worked for Medeor Pharma Limited and Medeor Limited undertaking commercial and scientific research on new business and investment opportunities. Jo was a cofounder of Nuformix, and is responsible for R&D, intellectual property and regulatory issues. Committees: Jo is a member of the Nomination Committee.

Madeleine “Maddy” Kennedy

Non-Executive Director